1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

US FDA: Please Pay PDUFA Program Fees ASAP

 
• By Derrick Gingery

Carryover funds are limited after the agency's collections schedule was altered by the late user fee program renewal.

Paying an invoice
Program fees generate the bulk of PDUFA revenue for the FDA. • Source: Shutterstock

Even though its user fee programs are renewed, the long wait to complete the process still is causing the US Food and Drug Administration some financial stress.

Agency officials notified sponsors on 7 October that invoices for the PDUFA program fee had been sent the same day....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

US FDA’s Prescription And Generic Drug User Fee Collections May Miss FY 2025 Targets

 
• By Sue Sutter

Both programs were expected to slightly under-collect fees, similar to FY 2024, but an assessment determined the capacity planning adjustment was accurately forecasting the necessary revenue.

October US FDA User Fee Goals: Few Novel Agents, But Many New Indications As Shutdown Looms

 
• By Bridget Silverman

October is unusually low on user fee goals for novel agents, but more than 20 applications for new indications and formulations will keep FDA staff busy, especially in oncology and ophthalmology.

Shutdown Approaches: US FDA Would Retain Most Of Recently Trimmed Staff

 
• By Derrick Gingery

FDA shutdown plans indicate about 86% of staff would be retained, a rate that is higher than previous plans, but reserve funding would not last more than a few months.

More NME Reviews, Reduced Costs Combine To Lower US FDA Voucher Fee

 
• By Derrick Gingery

The FDA said new molecular entity application reviews increased and cost less in fiscal year 2024, a potentially encouraging sign for industry.

More from Pathways & Standards

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 
• By Neena Brizmohun

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US FDA’s Tidmarsh Takes On Surrogate Endpoints, Maybe Old Business Partner, On LinkedIn

 
• By Sarah Karlin-Smith

CDER Director George Tidmarsh said in a now deleted social media post that his center will evaluate surrogate endpoints. Tidmarsh mentioned "notable failures," including a lupus drug, where he has past business connections to the sponsor's board chair.

Shutdown Approaches: US FDA Would Retain Most Of Recently Trimmed Staff

 
• By Derrick Gingery

FDA shutdown plans indicate about 86% of staff would be retained, a rate that is higher than previous plans, but reserve funding would not last more than a few months.